Both in Biotechnology
Repligen vs Kymera Therapeutics
Over the past year RGEN returned +19.0% and KYMR returned +121.0%; their daily moves had a correlation of 0.12.
RGEN +19.0% KYMR +121.0%Growth of $1, one year, split-adjusted
| Metric | RGEN | KYMR |
|---|---|---|
| Price | $178.72 | $131.99 |
| Market cap | $11.35B | $11.27B |
| Today | +0.25% | +3.85% |
| 1 month | +2.2% | +24.5% |
| 6 months | +42.1% | +53.0% |
| Year to date | +9.1% | +69.6% |
| 1 year | +19.0% | +121.0% |
| Revenue growth (YoY) | +10.9% | −100.0% |
| Gross margin | 53.0% | — |
| Net margin | −18.4% | — |
| P/E (TTM) | — | — |
| Price / sales | 14.1× | 110.2× |
| Net cash | $307.4M | $969.2M |
| Dividend yield | — | — |
| Volatility (60d) | 47.3% | 39.5% |
| Short % of float | 12.8% | 13.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).